SYSTEMIC LUPUS ERYTHEMATOSUS

This study looks at whether the shingles vaccine is safe and works well for people with lupus, a condition that affects the immune system. About 224 adults with lupus will receive either the vaccine or a placebo, and researchers will monitor for lupus flare-ups over 24 weeks. The…

This study tests an experimental oral medicine, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of BI 3000202 or a placebo, taken daily for a year, while continuing their usual lupus tre…

This study tests a new drug called MIL62 in people with systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. About 316 adults with active lupus will receive either MIL62 or a placebo, and researc…

This study is for people who have both an autoimmune disorder (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with othe…

This early-stage study is testing a new drug called A-319 for people with active or hard-to-treat systemic lupus erythematosus (SLE). The drug is a special antibody designed to target and help control the overactive immune cells causing the disease. The main goal is to see if it …

This early-stage trial tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The main goal is to see if the treatment is safe and tolerable. Researchers will also check if it helps control the…

This early-stage study tests a new type of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses the patient's own immune cells, modified to target and calm the overactive immune system. The goal is to reduce disease activ…

This study tests an experimental drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check safety and how the drug moves through the body, not to cure the disease. Participants will receive the drug as a shot under the skin, and the stu…

This study looks at whether people aged 60 and older with stable lupus can safely stop taking hydroxychloroquine, a drug that can cause eye damage over time. About 330 participants will either continue the drug or switch to a placebo and be monitored for one year for disease flar…

This early-phase study tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to temporarily reduce certain immune cells (B cells) that are overactive in these conditions. Participants receive two doses by IV, 21 days apar…

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…

This early-stage study tests a new drug called GSK5926371 in people with lupus and similar autoimmune diseases. The drug is designed to target and calm overactive immune cells that cause inflammation and damage. The main goal is to check safety and find the right dose in about 54…

This early-stage trial tests a new cell therapy for children and young adults (ages 2-30) with severe lupus that hasn't responded to standard treatments. Doctors take a patient's own T cells, genetically modify them to target and destroy harmful B cells, and then give them back. …

This early-stage study tests a new experimental drug (GSK4527363) for safety and how the body processes it. It includes healthy volunteers and people with active lupus or lung scarring linked to connective tissue disease. The goal is to find a safe dose and watch for side effects…

This early-phase trial tests a new treatment called Meta10-19 for people with moderate to severe lupus. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The study aims to find a safe dose and see if it can cont…

This study tests a new medicine called SHR-2173 for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 248 adults will receive either the drug or a placebo to see if it reduces disease activity without serious side effects. The main goal is…

This early-stage study tests whether a new drug called AZD5492 is safe and tolerable in adults with lupus, myositis, or rheumatoid arthritis. About 72 participants will receive either one or two doses of the drug and be monitored for side effects over 6 months. The goal is to gat…

This study compares a newer drug, telitacicept, to the standard treatment cyclophosphamide for lung scarring (interstitial lung disease) caused by lupus. About 100 adults with early lupus and mild-to-moderate lung involvement will receive one of the two drugs for a year. The goal…

This early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…

This early-stage study tests a new drug called surovatamig in 48 adults with rheumatoid arthritis or lupus. The main goal is to check safety and how the body handles the drug. Participants receive increasing doses to find the best and safest amount.

This early-stage study tests a new treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't responded to other therapies. Obe-cel uses a patient's own immune cells, modified to target and attack faulty B cells driving the disease. The trial aims…

This study tests whether the drug anifrolumab can improve blood vessel health and reduce inflammation in people with lupus, who face higher risks of heart attacks and strokes. About 45 adults with lupus will receive either anifrolumab or a placebo through IV infusions over 8 mont…

This early-stage study tests a single injection of stem cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can reduce disease activity and improve kidney function. Participants continue their usual medications and ar…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. The main goal is to check if the treatment is safe, and also to see if it helps control the disease. Participants receive a singl…

This study follows 300 people with active systemic lupus erythematosus (SLE) who are taking anifrolumab. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over 5 years. The goal is to see if anifrolumab works safely i…

This early-stage study tests a new drug called CPTX2309 in healthy people and those with moderate to severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The main goal is to check if the drug is safe and tolerable. About 64 adults will take part, receiving the …

This study is testing an investigational drug called anifrolumab in children aged 5 to 17 with moderate to severe systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if adding anifrolumab to standard treatments can better control lupus activity and reduc…

This study looks at the long-term safety of the drug ianalumab in people with systemic lupus erythematosus (SLE). It is for patients who have already completed a previous ianalumab study. About 550 participants will receive either ianalumab or a placebo to monitor side effects an…

This study tests whether an experimental drug called VENT-03 can reduce skin symptoms in people with cutaneous lupus (CLE), with or without systemic lupus (SLE). About 24 adults will receive either VENT-03 or a placebo for 4 weeks, then all will receive VENT-03 for 8 more weeks. …

This early-stage study is testing a new drug called budoprutug in 30 adults with active lupus who haven't responded well to other treatments. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might help…

This study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, found on faulty immune cells. The goal is to see if it is safe and can help control severe autoimmune diseases like lupus and scleroderma that have not …

This early-stage study tests a drug called alnuctamab in 21 adults with moderate to severe lupus that hasn't improved with standard treatments. The drug targets a protein on immune cells to reduce disease activity. The main goal is to check safety and side effects, while also see…

This early-stage study is testing a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune …

This study tests a weekly injection of anifrolumab in 245 adults with lupus who have never taken strong immune-suppressing drugs. The goal is to see if the drug can help patients reach remission and safely reduce or stop steroid use over 52 weeks. Participants must already be on …

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (lupus). The main goal is to check for side effects and how the drug moves through the body. About 112 participants will receive…

This study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty B cells that drive autoimmune diseases like lupus, scleroderma, and myositis. Up to 24 adults with active disease will receive the therapy after a short chemotherapy course.…

This study tests a new treatment combining specially designed immune cells (AD-PluReceptor NK cells) with a drug called tafasitamab and chemotherapy for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. The goal is to find a safe dose and see i…

This study tests whether a new drug called E6742 can help control lupus better than a placebo. About 256 adults with active lupus will receive either E6742 or a placebo, along with low-dose steroids. The main goal is to see if more people on E6742 have less disease activity after…

This study tests a new, quickly-made CAR-T cell therapy for people with severe lupus that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack lupus-causing cells. The main goals are to see if it's safe and if it ca…

This early-phase study tests a personalized cell therapy (CAR-T) for people with severe lupus that hasn't responded to standard treatments. The therapy uses the patient's own immune cells, modified to target and calm overactive B cells. The goal is to reduce disease activity and …

This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with kidney inflammation (lupus nephritis). The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the d…

This study tests a new treatment using specially engineered immune cells (CAR-NK) for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The treatment aims to control the overactive immune system and reduce…

This early-stage study tests a new, fast-made CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system causing lupus. The main goals are to…

This early-phase study tests whether a new drug called ONTO1 is safe for people with lupus nephritis or systemic lupus erythematosus (SLE). About 61 participants will receive ONTO1 alongside standard lupus treatments like mycophenolate mofetil. The goal is to find the highest saf…

This study tests a drug called belimumab in 350 adults who have had lupus for less than 2 years and still have active symptoms despite standard treatment. The goal is to see if adding belimumab can help more people reach a low disease activity state and reduce the need for steroi…

This early-stage study tests a new medicine called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and how well the body handles it. Participants will be followed for up to a year, and the study also loo…

This study tests a stem cell transplant to 'reset' the immune system in children and young adults (ages 8–25) with life-threatening lupus or scleroderma that hasn't responded to standard treatments. The approach uses high-dose therapy to wipe out faulty immune cells, then infuses…

This study tests two medications, inebilizumab and blinatumomab, in adults with hard-to-treat lupus or rheumatoid arthritis. The goal is to see if these drugs are safe and can help control disease activity. About 220 participants will receive the drugs by injection or infusion. T…

This study tests whether adding dapirolizumab pegol to standard lupus treatments can better control moderate-to-severe lupus symptoms over 48 weeks. About 450 adults with active lupus will receive either the drug or a placebo. The goal is to see if the drug reduces disease activi…

This early-stage study tests a new treatment called HN2301 in 30 people with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also see if the therapy can reduce disease activity by targeting immune cells.

This early-stage study tests a new medicine called MK-1045 in 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and tolerable at different doses. This is not a cure; it aims to understand how the drug works in the body and its side effect…

This study tests whether an online program that teaches better diet and self-care can reduce fatigue and improve quality of life for adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis. About 200 participants will u…

This study is building a large database and sample bank from 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will use this information to find links between patient outcomes and biological markers. The goal is to…

This study is for breastfeeding mothers with moderate to severe lupus who are already taking the medication anifrolumab. Researchers will measure how much of the drug passes into breast milk and into the baby's blood. The goal is to understand safety for infants, not to test a ne…

This study follows 442 pregnant women with moderate to severe lupus to see if the drug anifrolumab affects pregnancy or baby health. Some women took anifrolumab during pregnancy, others did not. Researchers will compare birth defects and other outcomes. No new treatment is given—…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease) and may receive immune checkpoint inhibitor drugs. Researchers want to see if the tool is easy to use and helpful for …

This study is creating a registry of 1,000 pregnant women with autoimmune diseases like lupus and rheumatoid arthritis. Researchers will track their health and pregnancy outcomes to identify risk factors and ways to improve care for both mothers and babies. The study does not tes…

This study is creating a new tool to help doctors diagnose and choose treatments for autoimmune diseases. Researchers will analyze blood samples from 500 children with autoimmune conditions and healthy children to find patterns in genes and other molecules. The goal is to make di…

This study is creating a registry of 1,000 people with lupus (systemic lupus erythematosus or cutaneous lupus) who are seen at Duke Rheumatology clinics. Researchers will collect medical information and blood samples over time to learn how lupus changes and affects patients. The …

This study looks at whether people with lupus have faster aging of their immune system. Researchers will measure specific immune cells and telomeres in 75 adults aged 18 to 60 with lupus. The goal is to better understand how lupus affects the body over time, not to test a new tre…

This study tracks 240 pregnant women with lupus who have taken the drug anifrolumab during pregnancy or shortly before conception. Researchers will monitor for birth defects and other pregnancy complications to better understand the drug's safety. The goal is to gather informatio…

This study monitors about 3,200 adults with moderate-to-severe lupus to see if the drug anifrolumab raises the risk of serious infections or cancer compared to standard treatments. Researchers will analyze medical records over time, focusing on hospitalizations, infections needin…

This study is working to create a new, objective way to measure pain in children with juvenile arthritis, lupus, or fibromyalgia. Researchers will follow 90 children for one year, collecting data during regular clinic visits. The goal is to replace the current trial-and-error app…

This study aims to understand why some lupus patients get false positive results on tests for HLA antibodies, which can make it harder to get an organ transplant. Researchers will look at blood samples from 30 lupus patients who have no known risk factors for these antibodies. Th…

This study looks at how changes in the TREX1 gene are linked to lupus, especially skin problems. Researchers will check disease activity in 90 adults with lupus using a standard scoring tool. No new treatment is tested; the goal is to better understand the disease.

This study aims to learn more about how lupus develops and changes over time by observing patients and their relatives. Researchers will collect medical history, blood, urine, and genetic samples from up to 2,000 participants aged 3 and older. The goal is to better understand the…

This study tests a program called CO-LEAD to improve how lupus patients and their doctors talk about medications. It trains doctors to use better communication strategies and gives patients a tool to share their medication challenges. The goal is to see if this leads to more help…

This study is a long-term registry for people with lupus (SLE) who are under a rheumatologist's care. Researchers will collect information during regular doctor visits to learn more about how the disease behaves and how well current treatments work in the real world. No experimen…